iBio Expands Cardiometabolic and Obesity Pipeline through Licensing Antibody from AstralBio

iBio (NASDAQ: IBIO) has announced a licensing agreement with AstralBio for a preclinical first-in-class antibody targeting Activin E, discovered using iBio's Machine-Learning Antibody Engine. The antibody shows promise in inducing fat-selective weight loss and protecting against obesity and cardiometabolic disease.

Preclinical studies demonstrated strong antibody binding, inhibition of Activin E signaling, and fat-specific weight loss in an obese rodent model. The antibody represents the first functional inhibitor of Activin E, a genetically validated therapeutic target important for energy balance and fat distribution regulation.

Under the agreement terms, AstralBio provided iBio a $750,000 credit toward the option fee and will be eligible for development and commercialization milestone payments up to $28 million, plus low to mid-single-digit sublicense fees. Additionally, iBio amended its collaboration with AstralBio to add a fifth target for cardiometabolic disease treatment.

https://www.stocktitan.net/news/IBIO/i-bio-expands-cardiometabolic-and-obesity-pipeline-through-licensing-ii0c65urteqi.html